Background
==========

Cancer patients, particularly those with hematological malignancies, are disproportionately at high risk of developing bloodstream infections (BSIs), with a risk of infection about ten times that of noncancer patients.[@b1-idr-11-1511] BSIs are common causes of in-hospital morbidity and mortality in such patients.[@b2-idr-11-1511] In addition, pathogens causing BSIs are increasingly becoming drug resistant making the problem much worse, especially in countries with limited resources.[@b3-idr-11-1511],[@b4-idr-11-1511]

Bacteria are the primary causative agents of BSIs, with significant fluctuations in the spectrum of the isolates over time.[@b5-idr-11-1511],[@b6-idr-11-1511] Gram-negative bacteria were the predominant causative agents of BSIs in the 1960s, but this later changed toward Gram-positive bacteria.[@b7-idr-11-1511],[@b8-idr-11-1511] However, there are still some studies in support of the Gram-negative predominance, especially in developing countries. In addition, due to increasing numbers of immunocompromised hosts, fungal pathogens, such as yeasts[@b9-idr-11-1511] (mainly *Candida* spp.) and molds (mainly *Aspergillus* spp.) have been indicated as the main causes of invasive fungal infection (IFI) in cancer patients.[@b10-idr-11-1511],[@b11-idr-11-1511] Frequent hospitalization, exposure to invasive procedures, use of broad-spectrum antibiotics, and chemotherapy have been indicated as the most important risk factors for infections in cancer patients.[@b12-idr-11-1511],[@b13-idr-11-1511] Chemotherapy renders cancer patients neutropenic, making them more susceptible to potentially life-threatening BSIs.[@b14-idr-11-1511],[@b15-idr-11-1511] The treatment of infections in patients with cancer often relies on the use of established guidelines with consideration of the local microbiology and antibiotic-sensitivity patterns of possible etiologic agents.[@b16-idr-11-1511] This is because the spectrum and drug-resistance profile of pathogens causing BSIs in such patients have shown significant fluctuations in different geographical areas and time points.[@b5-idr-11-1511],[@b17-idr-11-1511] Unlike this fact, in our study setting, almost all cancer patients with febrile episodes start empirical antibacterial therapy, and possible regimen change is done based on the clinical response of patients. Apart from our previous report on rare (uncommon) bacterial infections in the same setting,[@b18-idr-11-1511] to our knowledge there has been no comprehensive study to investigate the microbial spectrum and drug-resistance profile of pathogens causing BSIs in cancer patients from Ethiopia. This study determined the microbial spectrum and drug-resistance profile of pathogens causing BSIs in febrile cancer patients at a referral hospital in Ethiopia.

Methods
=======

Study setting, design, and population
-------------------------------------

This institution-based cross-sectional study was done at Tikur Anbessa Hospital in Addis Ababa, the only cancer-referral and -treatment center ever to function fully in Ethiopia. Data were collected between December 2011 and June 2012. All febrile cancer patients visiting the hospital's outpatient departments and those admitted to the Internal Medicine ward and Oncology Radiotherapy Center were investigated for inclusion. Adult febrile cancer patients (\>18 years old) who had not started antibiotics and providing informed consent (written) were included in the study. Samples were collected from 107 patients at first episodes of fever, both from neutropenic and nonneutropenic patients.

Specimen collection
-------------------

Two sets (10 mL each) of venous blood were collected aseptically within 24 hours from each patient. Samples drawn were then poured into blood culture bottles and incubated aerobically at 37°C. Daily inspection of culture bottles was done for up to 7 days. A structured questionnaire was also used to collect data on the sociodemographic and clinical characteristics of the patients, including age, sex, type of cancer, neutrophil counts, cancer therapy, and history of antibiotic therapy.

Blood culture and identification
--------------------------------

Gram staining was performed from the blood culture broths that showed visible growth. Evidence for growth was considered based on the appearance of colonies growing on top of red cells, turbidity, gas bubbles, or hemolysis. In addition, blind subculturing was done if a visible growth was not detected within 24 hours. Terminal subculturing was done for bottles that did not show visible growth within 7 days. Based on clues from Gram-staining results, we subcultured organisms on chocolate agar, blood agar, MacConkey agar, and Sabouraud dextrose agar (SDA). Two sets of SDA were inoculated for each sample, one incubated at 37°C and the other at room temperature. We incubated bacterial cultures aerobically at 37°C for up to 24--48 hours and the SDA for 2 weeks.

Gram-positive bacteria were identified using coagulase and catalase tests. Enterobacteriaceae isolates and non-fermentative Gram-negative bacilli were identified using analytical profile index (API20E) and API-NE identification kits (BioMérieux, Lyon, France), respectively. For initial identification of *Candida albicans*, the germ-tube test was used. The thermotolerance test was employed to differentiate *C. albicans* from *C. dubliniensis*. Identification of non-*C. albicans* at a species level was not possible, due to limitations of diagnostics in our setting.

Antimicrobial susceptibility testing
------------------------------------

For antimicrobial susceptibility testing, the disk diffusion method was used. Following the standard operating procedures, we mixed three to five bacterial colonies with 5 mL saline to prepare a suspension equivalent to a 0.5 McFarland standard. By using a sterile swab, the entire surface of the Mueller--Hin-ton agar was inoculated with bacterial suspensions. After the Mueller--Hinton agar had been dried for 3--5 minutes at room temperature, nine antibiotic disks (Oxoid) were dispensed on the surface of each plate. Amoxicillin--clavulanate (30 µg), chloramphenicol (30 µg), tetracycline (30 µg), sulfamethoxazole--trimethoprim (25 µg), ceftriaxone (30 µg), and ampicillin (10 µg) were used for both Gram-positive and Gram-negative bacterial isolates. Nalidixic acid (30 µg), gentamicin (10 µg), and ciprofloxacin (5 µg) were used only for Gram-negative isolates, whereas oxacillin (5 µg), and penicillin G (10 units) were used only for Gram-positive bacteria. The inoculated plates were incubated for 24--48 hours at 37°C. Isolates were classified as sensitive, intermediate, and resistant based on diameters of zones of inhibition measured by a caliper. The standardized table supplied by the Clinical Laboratory Standard Institute was used for estimation of zone of inhibition. We used *Staphylococcus aureus* (ATCC 25923), *Escherichia coli* (ATCC 25922), and *Pseudomonas aeruginosa* (ATCC 27853) as reference strains for quality control of culture and antimicrobial susceptibility testing. The identification of true coagulase-negative *Staphylococcus* (CoNS) was considered when there was growth in the two bottle sites.

Data analysis
-------------

After data entry had been completed using EpiData Entry version 3.1 software, it was transferred to SPSS version 16 for analysis. Risk factors for BSIs (culture-positive) were assessed in comparison with culture-negative (used as a control). Variables with *P*-values of \<0.25 in the bivariate analysis were included in the multivariate logistic regression to determine the association of potential factors with BSIs. *P*≤0.05 was considered statistically significant.

Ethical issues
--------------

The study was approved by the Addis Ababa University College of Health Science Ethical Review Committee. Written informed consent was obtained from all study participants or their caregivers if the patients were too ill to provide consent. Participation in the study was voluntary. The patients' culture and susceptibility testing results were immediately reported to physicians for treatment and management guidance.

Results
=======

Patient profiles
----------------

A total of 107 adult febrile cancer patients were included in the study: 55 (51.4%) females and 52 (48.6%) males. The mean age of study participants was 35.5 years. More than half (56 \[52.3%\]) the participants were neutropenic and 81 (75.7%) suffered from leukemia. All the patients who took cancer therapy 76 (71%) received only chemotherapy. The majority (95% \[72 of 76\]) of patients were in the first cycle of chemotherapy, and 57% (61 of 107) had taken antibiotics previously. Of these, the majority (64% \[39 of 61\]) received ceftriaxone only, 13% (11 of 61) received both ceftriaxone and vancomycin, and the rest (13% \[11 of 61\]) were given ceftriaxone, vancomycin, and ciprofloxacin, while 75% (81 of 107) had total parenteral nutrition during our investigation. However, none of them had either central intravenous or indwelling intravenous devices. [Table 1](#t1-idr-11-1511){ref-type="table"} shows detailed clinical characteristics of the study participants.

Microbial spectrum of BSI
-------------------------

The microbial spectrum of the BSIs is shown in [Table 2](#t2-idr-11-1511){ref-type="table"}. Of the study participants, 76 of 107 (71%) were culture-positive for bacteremia and/or fungemia. Overall, 112 blood cultures were performed and 82 pathogenic bacteria and/or fungi identified: 71 (87.6%) isolates were bacteria and 10 (12.3%) were fungi. Blood cultures were positive in 56 (73.7%) leukemia, 15 (19.8%) lymphoma, and five (6.5%) solid-tumor patients. Fifty (66.0%) of the culture-positive cases were neutropenic. The majority (60.5% \[43 of 71\]) of bacterial isolates were Gram-positive organisms, *S. aureus* being the predominant pathogen (72% \[31 of 43\]). The remaining Gram-positive pathogens (39.5%) were CoNS. Of 43 Gram-positive bacteria isolated, 65% (28 of 43) were from neutropenic patients (*P*=0.03).

Gram-negative bacteria accounted for 39.5% (28 of 71) of isolates in which nonfermenting Gram-negative bacilli (NF-GNBs) predominated (60.7% \[17 of 28\]). *Stenotrophomonas maltophilia* (17.9% \[five of 28\]) was the most frequent Gram-negative pathogen, followed by *Klebsiella pneumoniae* (7.1% \[three of 28\]). Of 28 Gram-negative bacteria, 75% (21 of 28) were isolated from neutropenic patients (*P*=0.005). Eleven (13.5%) of the isolates were fungi. *C. albicans* accounted for 63.6% (seven of eleven) of the pathogenic fungi isolated ([Table 2](#t2-idr-11-1511){ref-type="table"}). Ten (13.2%) of the 76 patients had polymicrobial infections: seven (70%) with bacterium--bacterium and three (3%) bacterium--fungus coinfections. Seven (70%) of the coinfections were due to *S. aureus* and NF-GNBs, two (20%) were due to *S. aureus* and *C. albicans,* and one (10%) was due to *K. pneumoniae* and *C. albicans*.

Risk factors for BSIs
---------------------

[Table 3](#t3-idr-11-1511){ref-type="table"} shows relationships between BSIs and participants' clinical and sociodemographic characteristics. Neutropenia was found to be an independent risk factor for BSIs in a multivariate analysis (*P*\<0.001). Being male was also significantly associated with BSIs (crude OR 2.8, 95% CI 0.69--6.5; *P*=0.042), but only in the bivariate analysis.

Antibiotic susceptibility of bacterial isolates
-----------------------------------------------

Antibiotic-resistance patterns of Gram-positive bacteria (n=43) against the eight antimicrobial agents is shown in [Table 4](#t4-idr-11-1511){ref-type="table"}. Overall, the highest rates of resistance were observed for ceftriaxone (67.4% \[29 of 43\]), oxacillin (67.4% \[28 of 43\]), and amoxicillin--clavulanic acid (62.7% \[26 of 43\]). *S. aureus* showed the highest rates of resistance for these three antibiotics as well. The lowest level of resistance was observed in sulfamethoxazole--trimethoprim (30.2% \[13 of 43\]).

[Table 5](#t5-idr-11-1511){ref-type="table"} shows results for those Gram-negative bacteria for which susceptibility testing was available (n=15). We did not perform susceptibility testing for *Sphignomonas* spp., as confirmatory methods are not yet available for this bacterium. In Gram-negative bacteria, the highest rates of resistance were observed for amoxicillin--clavulanic acid (80% \[12 of 15\]), followed by ceftriaxone (73.3%) and sulfamethoxazole--trimethoprim (73.3%). Ciprofloxacin was the most effective antibiotic for Gram-negative pathogens, with 86.6% sensitivity. All five isolates of *S. maltophilia* were 100% resistant to chloramphenicol. All *K. pneumoniae* (fermenting rod) isolates were also 100% resistant to chloramphenicol and ceftriaxone. Resistance for more than three (tetracycline, sulfamethoxazole--trimethoprim, and ceftriaxone) types of antibiotic (multidrug resistance) was observed in 26.3% (13 of 43) of the Gram-positive and 40% (six of 16) of the Gram-negative bacteria.

Discussion
==========

Except for a single report on rare bacterial pathogens by the same authors,[@b18-idr-11-1511] to our knowledge, this study is the first comprehensively to address microbial spectrum and drug-susceptibility patterns of pathogens causing BSIs in cancer patients from Ethiopia. Gram-positive bacteria (60%) were found to be the predominant pathogens causing BSIs among febrile cancer patients in our study setting. Similar research from developed countries has shown Gram-positive predominance (54%, Gram-positive vs 45% Gram-negative), but large variability among hospitals and countries has been noted.[@b19-idr-11-1511] In this regard, recent studies from the USA (72.8%)[@b20-idr-11-1511] and Turkey (74%)[@b21-idr-11-1511] showed that Gram-negative bacteria were predominant, while a report from UK[@b22-idr-11-1511] revealed the contrary.

On the other hand, similar reports from most developing countries still reveal the Gram-negative predominance.[@b23-idr-11-1511]--[@b25-idr-11-1511] The relatively lower use of indwelling medical devices, as well as low utilization of prophylactic antibiotic regimens in cancer patients, have been indicated as factors in the dominance of Gram-negative bacteria in these countries.[@b4-idr-11-1511],[@b26-idr-11-1511] Although these conditions hold true in our setting, the predominance of Gram-positive bacteria in our case might be due to several factors. First, more than half (57%) of the underlying cases in our study were with acute leukemia for which intensive chemotherapy was given and 33% of cases were older than 44 years. These two factors had already been identified as risk factors for severe mucositis,[@b27-idr-11-1511] which facilitates entry of oral normal flora to the blood. Moreover, unlike the current study, some studies from developing countries have included samples other than blood, such as urine and stool, which might have increased the proportion of isolated Gram-negative bacteria.[@b28-idr-11-1511]

*S. aureus* (43.6%) was the most frequently identified pathogen in this study, and this finding is similar to those reported from Sudan (72.7%),[@b29-idr-11-1511] North America (18%),[@b30-idr-11-1511] and Japan (35%).[@b31-idr-11-1511] However, the latest studies from the UK[@b22-idr-11-1511] and Ghana[@b14-idr-11-1511] and others from southeast Iran (12.3%),[@b32-idr-11-1511] South Africa (24.3%),[@b33-idr-11-1511] and Malaysia (23%)[@b34-idr-11-1511] showed that CoNS was the predominant Gram-positive pathogen. The relatively lower prevalence of CoNS (16.9%) in our study might have been due to the low proportion of catheterized patients.

Furthermore, *S. aureus* showed the highest rates of drug resistance. About 68% and 64.5% of *S. aureus* isolates were resistant to ceftriaxone and oxacillin, respectively. This finding is comparable to similar reports from Egypt,[@b35-idr-11-1511] Taiwan,[@b36-idr-11-1511] and Pakistan.[@b4-idr-11-1511] However, other studies have reported a lower resistance proportion for ceftriaxone.[@b30-idr-11-1511],[@b37-idr-11-1511],[@b38-idr-11-1511] This high resistance rate in our study could have been due to the fact that these antibiotics have already been in use for empirical therapy of patients with cancer in our setting. The higher resistance rate for ceftriaxone is an important issue, as this antibiotic has been commonly used to treat critically ill patients in our country.[@b39-idr-11-1511]

In similar studies conducted previously, the most predominant Gram-negative bacteria isolated from BSIs in patients with cancer were those in the Enterobacteriaceae family including *E. coil, K. pneumoniae,* and/or *P. aeruginosa*.[@b4-idr-11-1511],[@b20-idr-11-1511],[@b21-idr-11-1511],[@b40-idr-11-1511] In our study, NF-GNBs were the most frequent (61%) Gram-negative isolates. *S. maltophilia* (17.9%) was predominant in this group. This finding is in agreement with a previous report by the SENTRY surveillance program.[@b41-idr-11-1511] The shift to NF-GNBs (mainly *S. maltophilia*) in our study might have been due to the selective pressure imposed by overuse of broad-spectrum β-lactams in our setting.[@b42-idr-11-1511] In the current study, 57% of patients had received broad-spectrum β-lactams, and all *S. maltophilia* was isolated from such patients. In addition, the bacteria's capability to adhere easily to invasive medical devices and colonize fluids and irrigation solutions used in hospitals could have increased the risk of infections with these bacteria in our setting.[@b43-idr-11-1511] This increased proportion of NF-GNBs observed in our study is an important concern. Research has shown that most NF-GNBs are often intrinsically resistant to commonly used antimicrobial agents.[@b41-idr-11-1511] In our study, all five *S. maltophilia* isolates were 100% resistant to chloramphenicol, and the majority (80%) were resistant to ampicillin and ceftriaxone.

The overall proportion of IFIs in our study (13.5%) is comparable with recent studies from the USA (14%),[@b20-idr-11-1511] Brazil (12.8%),[@b42-idr-11-1511] and Japan (13%).[@b31-idr-11-1511] Yeasts (mainly *Candida* spp.) were the main cause of IFIs (63.6%), which is in agreement with studies in other areas.[@b10-idr-11-1511],[@b11-idr-11-1511] Only 18.2% of candidemia was due to non-*C. albicans* spp., which is contrary to many studies from developed countries that showed an apparent increase in the proportion of non-*C. albicans* spp. Increased use of azoles has been reported as a factor in the increasing trend of non-*C. albicans* spp.[@b10-idr-11-1511],[@b44-idr-11-1511] In the current study, none of the participants had used an antifungal agent, and this could have been the reason for the lower proportion of non-*C. albicans* spp. The predominance of *C. albicans* candidemia in our setting would however have practical importance, as it can be differentiated easily by a germ-tube test. Moreover, we also isolated an unusual opportunistic yeast pathogen (*Rhodotorula*) from a 21-year-old male neutropenic patient with acute myeloid leukemia. Tuon and Costa documented this pathogen as a cause of fungemia in immunocompromised patients.[@b45-idr-11-1511] In general, with an increasing population of immunocompromised, absence of sufficient choice of antifungal agents, and poor diagnostic facilities, such fungal isolates would become a challenge for our setup.

A substantial proportion of cases in the current study (13.2%) suffered from polymicrobial infections. Similarly, in a recent study from Barcelona, 10.2% BSIs in cancer patients were due to polymicrobial infections.[@b46-idr-11-1511] To make matters worse, about 40% of Gram-negative bacteria in the current study were multidrug resistance. This is comparable to that observed in Pakistan.[@b4-idr-11-1511] This high rate of polymicrobial infections and multidrug resistance is an important public health concern that needs to be addressed. Studies have shown that these infections have higher morbidity and mortality rates.[@b32-idr-11-1511],[@b40-idr-11-1511] Polymicrobial infections are difficult to treat, and the patient will develop compilations.[@b40-idr-11-1511] The implication of multidrug resistance is much worse. If patients do not respond to commonly used antibiotics, their ultimate fate will be severe complications and death.[@b47-idr-11-1511] Therefore, appropriate use of antibiotics should be ensured in our setting. Treatment of the patient should be based on actual information regarding the etiologic agent and antimicrobial testing. Ciprofloxacin was found to have a low resistance rate in this study, and hence could be a good choice for empirical treatment in our setting.

Many factors influence the prevalence, severity, and general patterns of microbial etiology of BSIs among cancer patients. Being neutropenic is an independent risk factor for BSIs.[@b48-idr-11-1511],[@b49-idr-11-1511] Neutrophils are the prime cells against invading microorganisms, expressly bacterial pathogens. A decrease in their number (neutropenia) is the most serious hematological toxicity, which is often observed in patients with cancer receiving chemotherapy.[@b50-idr-11-1511] Being male was also associated with BSIs in the bivariate analysis. Other research has also reported similar relationships.[@b1-idr-11-1511] The reason for this difference remains controversial, but possible factors, such as increased infective endocarditis in males,[@b51-idr-11-1511] higher likelihood of males to receive aggressive care, and differences in hormonal influence, have been postulated as possible reasons.[@b1-idr-11-1511],[@b51-idr-11-1511] Our study was not without limitations. Anaerobic microorganisms were not isolated, as we only used aerobic culture techniques. Since this study used blood samples only, the range of bacterial pathogens to be isolated was limited.

Conclusion
==========

Gram-positive bacteria were found to be the predominant pathogens isolated from BSIs in Ethiopian febrile cancer patients. Fungemia due to *C. albicans* was a common fungal BSI in our study setting. Neutropenia was significantly associated with BSIs. Both Gram-positive and Gram-negative bacteria showed an increasing level of resistance for most antibiotics that have been used for empirical therapy. Therefore, routine determination of the microbial and drug-resistance spectrum of pathogens should be an essential component of cancer-related infection control and care in our setting.
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###### 

Clinical characteristics of the patients (n=107)

                                                                               Frequency   Percentage
  ---------------------------------------------------------------------------- ----------- ------------
  **Leukemia**                                                                 81          75.7
  ALL                                                                          39          36.4
  AML                                                                          22          20.6
  CLL                                                                          14          13.1
  CML                                                                          6           5.6
  **Lymphoma**                                                                 17          15.9
  NHL                                                                          13          15.9
  HL                                                                           4           3.7
  **Solid tumors**                                                             9           8.4
  Adenocarcinoma                                                               4           3.7
  Breast cancer                                                                3           2.8
  Colonial cancer                                                              2           1.9
  **Absolute neutrophil count**                                                            
  Neutropenic (\<500 cells/µL)                                                 56          52.3
  Nonneutropenic (\>500 cells/µL)                                              51          47.7
  Total                                                                        107         100
  **Cancer therapy (within 7--14**                                                         
  **days of BSI)**                                                                         
  Yes                                                                          76          71.0
  No                                                                           31          29.0
  Total                                                                        107         100
  **Previous antibiotic therapy[a](#tfn1-idr-11-1511){ref-type="table-fn"}**               
  Yes                                                                          61          57.0
  No                                                                           46          43.0
  Total                                                                        107         100

**Notes:**

Within previous 3 months for \>7 days.

**Abbreviations:** ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BSI, bloodstream infection; CLL, chronic LL; CML, chronic ML; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma.

###### 

Distribution of bacterial and fungal pathogens causing bloodstream infections (n=107)

                                                       n (%)
  ---------------------------------------------------- -----------
  **Bacterial isolates**                               71 (86.5)
  Gram-positive bacteria                               43 (60.5)
  *Staphylococcus aureus*                              31 (72.1)
  Coagulase-negative *Staphylococcus*                  12 (27.9)
  Gram-negative bacteria                               28 (39.5)
  **Nonfermentative Gram-negative bacilli**            
  *Stenotrophomonas maltophilia*                       5 (17.9)
  *Acinetobacter baumannii*                            2 (7.1)
  *Burkholderia cepacia*                               2 (7.1)
  *Pseudomonas aeruginosa*                             1 (3.6)
  Rare bacterial isolates                              7 (41.2)
  Total                                                17 (60.7)
  **Fermentative Gram-negative bacilli**               
  *Klebsiella pneumoniae*                              3 (10.7)
  *Escherichia coli*                                   1 (3.6)
  *Citrobacter freundii*                               1 (3.6)
  Rare bacterial isolates                              6 (54.5)
  Total                                                11 (39.3)
  **Fungi**                                            11 (13.5)
  *Candida albicans*                                   7 (63.6)
  Non-*C. albicans*                                    2 (18.2)
  *Rhodotorula* spp.                                   1 (9.1)
  *Fusarium* spp.                                      1 (9.1)
  Polymicrobial isolates                               10 (13.2)
  *S. aureus*--nonfermentative Gram-negative bacilli   7 (70)
  *S. aureus*--*C. albicans*                           2 (20)
  *Klebsiella pneumoniae*--*C. albicans*               1 (10)

###### 

Risk factors associated with blood culture proven bloodstream infections

                                                                      Blood culture positive, n (%)   Blood culture negative, n (%)   COR (95% CI)        *P*-value
  ------------------------------------------------------------------- ------------------------------- ------------------------------- ------------------- -----------
  **Sex**                                                                                                                                                 
  Male                                                                42 (39.3)                       10 (9.3)                        2.8 (0.69--6.5)     0.042
  Female                                                              34 (32.7)                       20 (18.6)                                           
  Total                                                               76 (71.0)                       31 (29.0)                                           
  **Age-group, years**                                                                                                                                    
  18--24                                                              33 (30.8)                       15 (14)                                             
  24--44                                                              17 (15.9)                       9 (8.4)                                             
  \>45                                                                26 (22.4)                       9 (8.4)                         1.4 (0.48--3.92)    0.562
  Total                                                               76 (71.0)                       31 (29.0)                                           
  **Type of cancer**                                                                                                                                      
  Leukemia                                                            56 (52.3)                       25 (23.4)                       1.4 (0.29--6.11)    0.697
  Lymphoma                                                            15 (14)                         2 (1.9)                         9.6 (0.81--114.2)   0.073
  Solid tumors                                                        5 (4.7)                         4 (3.8)                                             
  Total                                                               76 (71.0)                       31 (29.0)                                           
  **Neutrophil count**                                                                                                                                    
  Neutropenic (\<500 cells/µL)                                        50 (46.7)                       6 (5.6)                         8.1 (4.43--31.6)    0.0001
  Nonneutropenic (\>500 cells/µL)                                     26 (26.2)                       25 (26.2)                                           
  Total                                                               76 (71.0)                       31 (29.0)                                           
  **Cancer therapy (within 7--14 days)**                                                                                                                  
  Yes                                                                 56 (51.4)                       20 (18.7)                       1.4 (0.52--3.16)    0.46
  No                                                                  20 (20.5)                       10 (8.4)                                            
  Total                                                               76 (71.0)                       31 (29.0)                                           
  **Antibiotic therapy[a](#tfn3-idr-11-1511){ref-type="table-fn"}**                                                                                       
  Yes                                                                 43 (40.2)                       18 (16.8)                       0.94 (0.28--1.95)   0.61
  No                                                                  33 (32.7)                       11 (13.5)                                           
  Total                                                               76 (71.0)                       31 (29.0)                                           

**Notes:**

Within previous 3 months for ≥7 days.

**Abbreviation:** COR, crude OR.

###### 

Susceptibility patterns of Gram-positive bacteria isolated from blood cultures (n=43)

                                       Antimicrobial drugs, n (%)                                                                                       
  ------------------------------------ ---------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  ***Staphylococcus aureus* (n=31)**   S                            10 (32.3)   19 (61.1)   19 (61.1)   8 (26)      17 (54.8)   9 (29)      8 (26)      16 (51.7)
  I                                    1 (3.2)                      ---         ---         2 (3.2)     2 (6.5)     3 (9.3)     2 (3.2)     3 (9.3)     
  R                                    20 (64.5)                    12 (38.9)   12 (38.9)   21 (67.8)   12 (38.7)   19 (61.3)   21 (67.8)   12 (39)     
  **CoNS (n=12)**                      S                            5 (39)      8 (67.7)    9 (75)      2 (16.7)    11 (91.7)   5 (42)      4 (33.3)    5 (42)
  I                                    ---                          ---         ---         2 (16.7)                ---         ---         ---         
  R                                    7 (61)                       4 (33.3)    3 (25)      8 (66.6)    1 (9.3)     7 (58)      8 (66.6)    7 (58)      
  **Total (n=43)**                     S                            15 (34.9)   27 (62.7)   28 (65.1)   10 (23.3)   28 (65.1)   14 (32.6)   15 (34.9)   21 (48.8)
  I                                    1 (2.4)                      ---         ---         4 (9.3)     2 (6.4)     3 (7)       ---         3 (7)       
  R                                    27 (62.7)                    16 (37.3)   15 (34.9)   29 (67.4)   13 (30.2)   26 (60.4)   29 (67.4)   19 (44.2)   

**Abbreviations:** S, sensitive; I, intermediate; R, resistant; CoNS, coagulase-negative *Staphylococcus*; AMC, amoxicillin--clavulanic acid; Amp, ampicillin; C, chloramphenicol; Cro, ceftriaxone; SXT, sulfamethoxazole--trimethoprim; P, penicillin; Ox, oxacillin; Ttc, tetracycline.

###### 

Susceptibility patterns of Gram-negative bacteria isolated from blood cultures (n=15)

                                             Antimicrobial drugs, n (%)                                                                                               
  ------------------------------------------ ---------------------------- ----------- ----------- ---------- ---------- ---------- ----------- ----------- ---------- ----------
  ***Stenotrophomonas maltophilia* (n=5)**   S                            1 (20)      1 (20)      1 (20)     4 (80)     ---        3 (60)      5 (100)     2 (40)     3 (60)
  I                                          ---                          ---         ---         ---        ---        ---        ---         1 (20)      1 (20)     
  R                                          4 (80)                       4 (80)      4 (80)      1 (20)     5 (100)    2 (40)     ---         2 (40)      1 (20)     
  ***Klebsiella pneumoniae* (n=3)**          S                                        1 (33.3)    ---        1 (33.3)   3 (66.7)   4 (100)     2 (66.7)               1 (33.3)
  I                                          ---                          ---         ---         1 (33.3)   ---        ---        ---         ---         1 (33.3)   
  R                                          3 (100)                      2 (66.7)    3 (100)     1 (33.3)   1 (33.3)   ---        1 (33.3)    3 (100)     1 (33.3)   
  ***Acinetobacter baumannii* (n=2)**        S                            1 (50)      1 (50)      2 (100)    1 (50)     2 (100)    2 (100)     2 (100)                1 (50)
  I                                          ---                          ---         ---         ---        ---        ---        ---         ---         ---        
  R                                          1 (50)                       1 (50)      ---         1 (50)     ---        ---        ---         2 (100)     1 (50)     
  ***Burkholderia cepacia* (n=2*)***         S                            ---         ---         ---        1 (50)     1 (50)     2 (100)     2 (100)     1 (50)     ---
  I                                          ---                          ---         ---         ---        ---        ---        ---         ---         ---        
  R                                          2 (100)                      2 (100)     2 (100)     1 (50)     1 (50)     ---        ---         1 (50)      2 (100)    
  ***Pseudomonas aeruginosa* (n=1)**         S                            ---         ---         ---        ---        1 (100)    ---         1 (100)                1 (100)
  I                                          ---                          ---         ---         ---        ---        ---        ---         ---         ---        
  R                                          1 (100)                      1 (100)     1 (100)     1 (100)    ---        1 (100)    ---         1 (100)     ---        
  ***Citrobacter freundii* (n=1)**           S                            ---         ---         ---        1 (100)    ---        1 (100)     1 (100)     ---        1 (100)
  I                                          ---                          ---         ---         ---        ---        ---        ---         ---         ---        
  R                                          1 (100)                      1 (100)     1 (100)     ---        1 (100)    ---        ---         1 (100)     ---        
  ***Escherichia coli* (n=1)**               S                            ---         ---         1 (100)    ---        ---        ---         1 (100)     ---        1 (100)
  I                                          ---                          ---         ---         ---        ---        ---        ---         ---                    
  R                                          1 (100)                      1 (100)     ---         1 (100)    1 (100)    1 (100)    ---         1 (100)     ---        
  **Total (n=15)**                           S                            3 (2.0)     5 (33.3)    6 (4.0)    8 (53.3)   6 (4.0)    11 (73.3)   13 (86.7)   3 (20.1)   9 (60.0)
  I                                          ---                          ---                     1 (6.7)    ---        ---        1 (6.7)     1 (6.6)     2 (13.3)   
  R                                          12 (80.0)                    10 (66.7)   11 (73.3)   6 (4.0)    9 (60.0)   4 (26.7)   1 (11.5)    11 (73.3)   4 (26.7)   

**Abbreviations:** S, sensitive; I, intermediate; R, resistant; AMC, amoxicillin--clavulanic acid; Amp, ampicillin; C, chloramphenicol; Cro, ceftriaxone; SXT, sulfamethoxazole-- trimethoprim; Ttc, tetracycline, Cip, ciprofloxacin; Gn, gentamicin; NA, nalidixic acid.
